Loading clinical trials...
Loading clinical trials...
A Phase 3, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Larazotide Acetate for the Relief of Persistent Symptoms in Patients With Celiac Disease on a GFD
Conditions
Interventions
Larazotide
Matching Placebo
Locations
160
United States
Research Site
Saraland, Alabama, United States
Research Site
Scottsdale, Arizona, United States
Research Site
Tucson, Arizona, United States
Research Site
Tucson, Arizona, United States
Research Site
North Little Rock, Arkansas, United States
Research Site
Bellflower, California, United States
Start Date
May 29, 2019
Primary Completion Date
July 21, 2022
Completion Date
July 21, 2022
Last Updated
July 26, 2022
NCT07239336
NCT06356220
NCT07069127
NCT06059716
NCT04014413
NCT06500754
Lead Sponsor
9 Meters Biopharma, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions